Table 3.
Prevalence of CTCAE-graded urinary toxicities in flare patients following SBRT for prostate cancer.
| Toxicity | Follow-up (months) | 1 | 3 | 6 | 9 | 12 | 18 | 24 |
|---|---|---|---|---|---|---|---|---|
| Grade | ||||||||
| Hematuria | 0 | 92.6% | 100.0% | 96.2% | 85.7% | 93.1% | 89.7% | 96.4% |
| 1 | 7.4% | 0.0% | 0.0% | 10.7% | 6.9% | 10.3% | 3.6% | |
| 2 | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| 3 | 0.0% | 0.0% | 3.8% | 3.6% | 0.0% | 0.0% | 0.0% | |
| Dysuria | 0 | 74.1% | 85.2% | 80.8% | 75.0% | 79.3% | 82.8% | 96.4% |
| 1 | 25.9% | 14.8% | 19.2% | 25.0% | 20.7% | 13.8% | 3.6% | |
| 2 | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 3.4% | 0.0% | |
| Incontinence | 0 | 77.8% | 81.5% | 76.9% | 57.1% | 72.4% | 62.1% | 82.1% |
| 1 | 22.2% | 18.5% | 23.1% | 39.3% | 27.6% | 37.9% | 14.3% | |
| 2 | 0.0% | 0.0% | 0.0% | 3.6% | 0.0% | 0.0% | 3.6% | |
| Urinary frequency/urgency | 0 | 14.3% | 44.4% | 34.6% | 25.0% | 24.1% | 41.4% | 57.1% |
| 1 | 75.0% | 51.9% | 61.5% | 60.7% | 58.6% | 48.3% | 42.9% | |
| 2 | 10.7% | 3.7% | 3.8% | 14.3% | 17.2% | 10.3% | 0.0% | |
| Retention | 0 | 37.0% | 51.9% | 42.3% | 46.4% | 41.4% | 17.2% | 46.4% |
| 1 | 7.4% | 22.2% | 30.8% | 17.9% | 3.4% | 17.2% | 17.9% | |
| 2 | 55.6% | 25.9% | 26.9% | 35.7% | 55.2% | 65.5% | 35.7% | |